Literature DB >> 14983949

The Finnish trial of prostate cancer screening: where are we now?

P Finne1, U H Stenman, L Määttänen, T Mäkinen, T L J Tammela, P Martikainen, M Ruutu, M Ala-Opas, J Aro, P J Karhunen, J Lahtela, P Rissanen, H Juusela, M Hakama, A Auvinen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14983949     DOI： 10.1111/j.1465-5101.2003.04397.x

Source DB:  PubMed          Journal:  BJU Int        ISSN： 1464-4096            Impact factor:   5.588


× No keyword cloud information.
  10 in total

1.  Impact of Prostatic-specific Antigen Threshold and Screening Interval in Prostate Cancer Screening Outcomes: Comparing the Swedish and Finnish European Randomised Study of Screening for Prostate Cancer Centres.

Authors:  Lasse Saarimäki; Jonas Hugosson; Teuvo L Tammela; Sigrid Carlsson; Kirsi Talala; Anssi Auvinen
Journal:  Eur Urol Focus       Date:  2017-08-10

2.  Prostate cancer: modeling the outcomes of prostate cancer screening.

Authors:  Stacy Loeb; Sigrid Carlsson; R Scott Braithwaite
Journal:  Nat Rev Urol       Date:  2012-03-13       Impact factor: 14.432

3.  Characteristics of men responding to an invitation to undergo testing for prostate cancer as part of a randomised trial.

Authors:  Eleanor I Walsh; Emma L Turner; J Athene Lane; Jenny L Donovan; David E Neal; Freddie C Hamdy; Richard M Martin
Journal:  Trials       Date:  2016-10-13       Impact factor: 2.279

4.  ANO7 is associated with aggressive prostate cancer.

Authors:  Elina Kaikkonen; Tommi Rantapero; Qin Zhang; Pekka Taimen; Virpi Laitinen; Markku Kallajoki; Dhanaprakash Jambulingam; Otto Ettala; Juha Knaapila; Peter J Boström; Gudrun Wahlström; Csilla Sipeky; Juha-Pekka Pursiheimo; Teuvo Tammela; Pirkko-Liisa Kellokumpu-Lehtinen; Vidal Fey; Lovise Maehle; Fredrik Wiklund; Gong-Hong Wei; Johanna Schleutker
Journal:  Int J Cancer       Date:  2018-09-22       Impact factor: 7.396

5.  Long-term health-related quality of life among men with prostate cancer in the Finnish randomized study of screening for prostate cancer.

Authors:  Kirsi Talala; Sirpa Heinävaara; Kimmo Taari; Teuvo L J Tammela; Paula Kujala; Ulf-Håkan Stenman; Nea Malila; Anssi Auvinen
Journal:  Cancer Med       Date:  2020-06-04       Impact factor: 4.452

6.  Does Protocol Make a Difference? Comparison of Two Prostate Cancer Active Surveillance Cohorts: A Non-protocol-based Follow-up and a Protocol-based Contemporary Follow-up.

Authors:  Inari Kalalahti; Hanna Vasarainen; Andrew M Erickson; Arttu Siipola; Kari A O Tikkinen; Antti Rannikko
Journal:  Eur Urol Open Sci       Date:  2021-10-28

7.  Novel prostate cancer susceptibility gene SP6 predisposes patients to aggressive disease.

Authors:  Csilla Sipeky; Teuvo L J Tammela; Anssi Auvinen; Johanna Schleutker
Journal:  Prostate Cancer Prostatic Dis       Date:  2021-05-19       Impact factor: 5.455

8.  Reducing overdiagnosis by polygenic risk-stratified screening: findings from the Finnish section of the ERSPC.

Authors:  Nora Pashayan; Paul Dp Pharoah; Johanna Schleutker; Kirsi Talala; Teuvo Lj Tammela; Liisa Määttänen; Patricia Harrington; Jonathan Tyrer; Rosalind Eeles; Stephen W Duffy; Anssi Auvinen
Journal:  Br J Cancer       Date:  2015-08-20       Impact factor: 7.640

9.  Sojourn-time-corrected receiver operating characteristic curve (ROC) for prostate specific antigen (PSA) test in population-based prostate cancer screening.

Authors:  Hsiao-Hsuan Jen; Wei-Jung Chang; Chen-Yang Hsu; Amy Ming-Fang Yen; Anssi Auvinen; Tony Hsiu-Hsi Chen; Sam Li-Sheng Chen
Journal:  Sci Rep       Date:  2020-11-26       Impact factor: 4.379

10.  Prostate cancer risk prediction using a polygenic risk score.

Authors:  Csilla Sipeky; Kirsi M Talala; Teuvo L J Tammela; Kimmo Taari; Anssi Auvinen; Johanna Schleutker
Journal:  Sci Rep       Date:  2020-10-13       Impact factor: 4.379
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.